Detailed Narrative
Strong Q3 FY26 Performance & 9M FY26 Progress
Senores Pharmaceuticals reported a robust Q3 FY26, with consolidated income reaching INR175 crores, a 64% year-on-year increase. EBITDA grew by 86% to INR54 crores, resulting in an improved EBITDA margin of 30.9%, up 360 basis points. Profit after tax also saw significant growth of 85% to INR32 crores. For the nine-month period, consolidated income stood at INR474 crores (up 65% YoY), with EBITDA at INR138 crores (up 87% YoY) and PAT at INR84 crores (more than doubled). The company remains on track to achieve its FY26 targets of 50% top-line growth and 100% PAT growth over FY25.
Strategic Expansion in Regulated Markets and CDMO-CMO Segment
Revenue from regulated markets grew by 60.5% YoY to INR113 crores in Q3 FY26, driven by product portfolio expansion and strategic go-to-market strategies. The CDMO-CMO segment continues to be a key differentiator, offering end-to-end solutions from development to regulatory support. The current revenue mix in regulated markets is approximately 55% from own products and 45% from CDMO-CMO; this is expected to shift towards 65% own products and 35% CDMO-CMO with the Apnar acquisition. The EBITDA margin for the US-regulated business is currently around 40% and is expected to sustain or improve by 1%.
Apnar Pharma Acquisition Enhances Capacity and Market Access
Senores completed the acquisition of a 75% stake in Apnar Pharma, with the remaining 25% expected by Q2 FY27. This acquisition provides a US FDA-approved facility, also approved by UK MHRA and Health Canada, enabling deeper penetration into regulated markets. Apnar is expected to contribute INR120-150 crores in revenue in FY27, with 3 products already launched from its facility this quarter. The acquisition also includes five approved ANDAs, projected to generate $16-18 million in revenue over the next 12-15 months, and offers flexibility to shift manufacturing from the US to India for select products.
Growth in Emerging Markets and India Branded Generics
The emerging market business recorded a 47.5% YoY revenue growth, reaching INR38 crores in Q3 FY26. This segment achieved its highest-ever quarterly revenue, EBITDA, and PAT, and is now cash-flow positive. The strong performance is attributed to the commercialization of 56 new product approvals received last quarter. The company aims for an EBITDA margin of close to 20% in the emerging markets. India's branded generics business also saw significant growth, increasing more than six-fold YoY to INR10.5 crores in Q3 FY26, with expectations of reaching INR40-50 crores in FY27.
Robust Product Pipeline and Future Launches
Senores' ANDA portfolio has quadrupled from 12 in December 2024 to 46 in December 2025. The company has 28 approved ANDAs ready for launch and 22 molecules under development, providing a strong pipeline. Management expects to launch all 28 approved ANDAs within the next 6-8 quarters, and at least 10 of the 22 under-development products within the same timeframe. The launch of Deferiprone in Q3 FY26, an organic development, further demonstrates the company's capability for new product introductions.
Capital Management and Financial Strategy
The company maintains a strong focus on cash flow generation, with operating cash flow for 9M FY26 at INR51 crores. To support future growth and working capital, the promoter group is infusing INR75-100 crores through a warrant structure, supplementing the remaining IPO proceeds of INR25 crores. Capex for the next 2-3 years is projected to be INR50-100 crores, which includes expanding the Atlanta facility to 2 billion tablets capacity. The company also noted a net versus capital cycle of 90-94 days.